PolyActiva has recently been awarded a $1.5m CUREator Grant, which will be used to progress its second generation ocular implant as a treatment for patients with glaucoma, targeting sustained daily dosing for 12 months.
PolyActiva has recently been awarded a $1.5m CUREator Grant, which will be used to progress its second generation ocular implant as a treatment for patients with glaucoma, targeting sustained daily dosing for 12 months.
© 2023 PolyActiva. All Rights Reserved. Caution: PolyActiva products are not for sale in the US